Converting Basic Science into Commercial and Clinical Reality

Publications and Patents arising from Contract R&D performed in the Immunovirology Laboratory

Cpn10
Immunotherapy

Johnson BJ, Le TT, Dobbin CA, Banovic T, Howard CB, Leon Flores FD, Vanags D, Naylor DJ, Hill GR, Suhrbier A . Heat shock protein 10 Inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem. 2005. 280(6):4037-47 Prov 13432AU  

Phase I and II Clinical Trials.
CBio Ltd.

PEP005
Chemotherapy

Ogbourne SM, Suhrbier A , Jones B, Cozzi SJ, Boyle GM, Morris M, McAlpine D, Johns J, Scott TM, Sutherland KP, Gardner JM, Le TT, Lenarczyk A, Aylward JH, Parsons PG. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004 Apr 15;64(8):2833- 9. PCT/AU01/00678-80  

Phase I and II Clinical Trials.
Peplin Biotech.

NY-ESO-1
ISCOM
Vaccine

Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjolander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A . NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell- mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res. 2004. 10(8):2879-90. WO0048630  

Phase I Clinical Trial.
CSL Ltd.

Kunjin Replicons
Vaccine

Anraku I, Harvey TJ, Linedale R, Gardner J, Harrich D, Suhrbier A , Khromykh AA. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol. 2002 Apr;76(8):3791-9. PCT/AU02/01598  

RepliKun Ltd 2005

Pam2Cys Peptides
Vaccine

Jackson DC, Lau YF, Le T, Suhrbier A , Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004. 101(43):15440-5.  

VacTX

Polytope
Vaccine

Suhrbier A. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev Vaccines. 2002 Aug;1(2):207-13. WO9524925  

Vaccine Solutions